Literature DB >> 8096574

Background mortality in clinical survival studies.

H A Verheul1, E Dekker, P Bossuyt, A C Moulijn, A J Dunning.   

Abstract

In long-term follow-up studies of survival after an initial event (eg, an operation) mortality from causes other than the one under study obscures the results, especially in elderly patients. In the traditional approach to the calculation of expected mortality a fictitious cohort is drawn from the general population, being matched for age, sex, and calendar time at the time of the initial event. The membership of this cohort is then kept constant from the initial event until the closing date of the study. The survival and mortality of this static cohort is then compared with that of the dynamic patient cohort to throw light on mortality from extraneous causes. This method can lead to severe bias if there is a strong correlation between the duration of observation of the patients and their age. The analysis can be improved by applying rate adjustment when calculating the background component of mortality. In this approach mortality rates from the general population are adjusted (weighted) so that the age, sex, and calendar year are at all times identical with those of each of the patients still alive and under observation. This is illustrated by means of a simplified example and a real-life one from a study at survival after aortic valve replacement. Estimation of rate-adjusted background mortality provides a framework that may put long-term survival, especially of elderly patients, in proper perspective.

Entities:  

Mesh:

Year:  1993        PMID: 8096574     DOI: 10.1016/0140-6736(93)93073-a

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  13 in total

1.  Adjusting and comparing survival curves by means of an additive risk model.

Authors:  P H Zahl; O O Aalen
Journal:  Lifetime Data Anal       Date:  1998       Impact factor: 1.588

2.  The utility of prognostic indices, early events, and histological subtypes on predicting outcomes in non-follicular indolent B-cell lymphomas.

Authors:  Sean I Tracy; Melissa C Larson; Andrew L Feldman; Matthew J Maurer; Anne J Novak; Susan L Slager; Jose C Villasboas; Cristine Allmer; Thomas M Habermann; Umar Farooq; Sergei Syrbu; James R Cerhan; Brian K Link
Journal:  Am J Hematol       Date:  2019-04-10       Impact factor: 10.047

3.  Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy.

Authors:  Matthew J Maurer; Hervé Ghesquières; Jean-Philippe Jais; Thomas E Witzig; Corinne Haioun; Carrie A Thompson; Richard Delarue; Ivana N Micallef; Frédéric Peyrade; William R Macon; Thierry Jo Molina; Nicolas Ketterer; Sergei I Syrbu; Olivier Fitoussi; Paul J Kurtin; Cristine Allmer; Emmanuelle Nicolas-Virelizier; Susan L Slager; Thomas M Habermann; Brian K Link; Gilles Salles; Hervé Tilly; James R Cerhan
Journal:  J Clin Oncol       Date:  2014-02-18       Impact factor: 44.544

4.  Early event status informs subsequent outcome in newly diagnosed follicular lymphoma.

Authors:  Matthew J Maurer; Emmanuel Bachy; Hervé Ghesquières; Stephen M Ansell; Grzegorz S Nowakowski; Carrie A Thompson; David J Inwards; Cristine Allmer; Catherine Chassagne-Clément; Emmanuelle Nicolas-Virelizier; Catherine Sebban; Laure Lebras; Clementine Sarkozy; William R Macon; Andrew L Feldman; Sergei I Syrbu; Alexandra Traverse-Glehan; Bertrand Coiffier; Susan L Slager; George J Weiner; Thomas E Witzig; Thomas M Habermann; Gilles Salles; James R Cerhan; Brian K Link
Journal:  Am J Hematol       Date:  2016-09-03       Impact factor: 10.047

5.  Measures of early postoperative mortality: beyond hospital fatality rates.

Authors:  V Seagroatt; M Goldacre
Journal:  BMJ       Date:  1994-08-06

6.  Classification of papillary cancer of the thyroid based on prognosis.

Authors:  S Noguchi; N Murakami; H Kawamoto
Journal:  World J Surg       Date:  1994 Jul-Aug       Impact factor: 3.352

7.  Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) enrolled on randomized clinical trials.

Authors:  M J Maurer; T M Habermann; Q Shi; N Schmitz; D Cunningham; M Pfreundschuh; J F Seymour; U Jaeger; C Haioun; H Tilly; H Ghesquieres; F Merli; M Ziepert; R Herbrecht; J Flament; T Fu; C R Flowers; B Coiffier
Journal:  Ann Oncol       Date:  2018-08-01       Impact factor: 32.976

8.  Appraising relative and excess mortality in population-based studies of chronic diseases such as end-stage renal disease.

Authors:  Caroline Elie; Y De Rycke; Jp Jais; P Landais
Journal:  Clin Epidemiol       Date:  2011-05-10       Impact factor: 4.790

9.  Defining cure in multiple myeloma: a comparative study of outcomes of young individuals with myeloma and curable hematologic malignancies.

Authors:  Praful Ravi; Shaji K Kumar; James R Cerhan; Matthew J Maurer; David Dingli; Stephen M Ansell; S Vincent Rajkumar
Journal:  Blood Cancer J       Date:  2018-02-28       Impact factor: 11.037

10.  Risk-dependent curability of radiotherapy for elderly patients with early-stage extranodal nasal-type NK/T-cell lymphoma: A multicenter study from the China Lymphoma Collaborative Group (CLCG).

Authors:  Bo Chen; Su-Yu Zhu; Mei Shi; Hang Su; Ying Wang; Xia He; Li-Ming Xu; Zhi-Yong Yuan; Li-Ling Zhang; Gang Wu; Bao-Lin Qu; Li-Ting Qian; Xiao-Rong Hou; Fu-Quan Zhang; Yu-Jing Zhang; Yuan Zhu; Jian-Zhong Cao; Sheng-Min Lan; Jun-Xin Wu; Tao Wu; Shu-Nan Qi; Yong Yang; Xin Liu; Ye-Xiong Li
Journal:  Cancer Med       Date:  2018-10-24       Impact factor: 4.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.